SIPP Industries, Inc. announced the appointment of Adam Graziano as the new Chief Executive Officer, effective immediately. Jakob Jorgensen, the former CEO of SIPP Industries, will remain a business consultant while also joining Calypso Pharmaceuticals as their new CEO. Mr. Jorgensen's new role will focus on advancing the recent research and development agreement between Calypso Pharmaceuticals and SIPP Industries.

This collaboration aims to develop a groundbreaking topical treatment utilizing Peptide P16, designed to penetrate and destroy melanoma cells. Additionally, the partnership will explore the potential of other peptides in combating obesity, anxiety, Alzheimer?s disease, and various other conditions. Adam Graziano brings a wealth of experience and leadership to SIPP Industries.

With 20 years in various business leadership roles and over 33 years in the insurance sector, while currently managing a $500 million portfolio, Mr. Graziano has consistently demonstrated his ability to guide teams in achieving and surpassing growth and financial objectives. He holds a Bachelor of Arts in Political Science with a minor in Criminal Justice from St. Cloud State University.